Business Wire

NY-ESTÉE-LAUDER

4.3.2021 13:02:17 CET | Business Wire | Press release

Share
The Estée Lauder Companies Announces New Equity and Engagement Center of Excellence

The Estée Lauder Companies (NYSE:EL) announced today that it has established a new Equity and Engagement Center of Excellence (COE). The creation of this new capability underscores The Estée Lauder Companies’ (ELC) core values and commitments to build greater equity and representation within every aspect of its business, from its employees to its consumers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005218/en/

The Equity and Engagement COE will be led by Nicole Monson , who has been appointed Senior Vice President, Equity and Engagement. Nicole will report directly to Michael O’Hare, Executive Vice President, Global Human Resources.

The events of 2020 and the movement around racial equality have placed a necessary spotlight on every company’s responsibility to take action to advance equal representation, advocacy and inclusion across their organizations. From examining and evolving how the company engages with employees around the world, to enabling greater collaboration across its brands, regions and functions, ELC remains dedicated to purposeful, strategic and accelerated action to drive lasting change.

Building upon ELC’s existing Commitment to Act on Racial Equity , actions on pay equity and other activities to date, the creation of the Equity and Engagement COE signals ELC’s investment in a focused and holistic approach to drive sustainable progress and advance the company’s diverse talent through deep engagement, career advancement, development programs, hiring practices and beyond.

“Our collective vision is to be the most inclusive, equitable and diverse global prestige beauty company for our employees and consumers alike. This important new capability will enhance employee engagement and build greater equity across the business today, while also providing a strategic platform to expand and scale this work into the future,” said Fabrizio Freda, President and Chief Executive Officer . “We know that authentic change takes time, dedication and a clear strategy, and we will continue to devote focused and meaningful resources toward accelerating this goal.”

“Since our company’s founding, our talented employees have been at the center of our business and the most important driver of our success. While we are proud of the progress we have made as a company thus far, we are committed to driving equity and engagement for the long-term,” said William P. Lauder, Executive Chairman . “Nicole’s deep experience and extensive knowledge of Human Resources and the global legal environment, combined with her demonstrated ability to positively influence ELC’s culture, have been invaluable to the company. I look forward to her continued leadership at the helm of this new Center of Excellence.”

As Senior Vice President, Equity and Engagement, Nicole will be an important member of ELC’s Senior Leadership Team and she will work across all areas of the business to develop the company’s long-term Equity and employee Engagement strategy and enterprise-wide capabilities. She will lead the development and implementation of proactive Equity and Engagement initiatives to create a workforce that is more representative and responsive to people of all backgrounds, where all have an opportunity to succeed.

The Equity and Engagement COE was designed to be a strategic and complementary enterprise-wide partner to ELC’s other leaders and business units focused on ESG-related matters, including Human Resources, the Inclusion, Diversity & Equity (IDE) COE, Global Communications, Global Citizenship and Sustainability (GCCS), Global Public Affairs, and beyond. In this spirit, Nicole will collaborate closely with Human Resources leaders and the IDE COE to develop programs designed to ensure fair, inclusive, and equitable treatment of employees around the world with emphasis on addressing conflict and implementing support systems for employees of color, ensuring equitable compensation, application of policies and access to career paths and ensuring the execution of ELC’s equity and engagement vision and strategy. Additionally, Nicole will lead the company’s Racial Equity Initiative, which includes finalizing and implementing a strategy to ensure ELC achieves its Racial Equity Commitments.

Nicole has an extensive proven track record of providing business partners with strategic legal counsel on a wide range of employment and compliance topics, a background that will serve her well in her new role. In her most recent position as Senior Vice President, Deputy General Counsel, Global Employment, Ethics and Legal Privacy, Nicole oversaw the Employment Law, Ethics and Legal Privacy teams and worked to advance the Legal strategy for employment, ethics and privacy globally to protect the company’s interests and mitigate risks associated with new laws and regulations, growth of digital platforms, new global acquisitions and an increased regulatory environment. Since joining the company in 2014 as Vice President, Employment Counsel, her role has continuously expanded and evolved with new responsibilities.

Nicole’s influence on ELC’s organizational culture has extended far beyond her official role and responsibilities. As a member of ELC’s Diversity Council, as well as ELC’s ‘Network of Black Leaders & Executives’ and ‘Women’s Leadership Network’ Employee Resource Groups, Nicole has long been passionate about promoting a culture of respect, inclusivity and belonging. Recently, she became Executive Sponsor of She’s Howard: Own Your Power , ELC’s partnership with Howard University to support the success of the University’s alumnae through experiential learning, career coaching, professional training and self-empowering mentorship opportunities.

In addition to her many contributions to ELC, Nicole is a highly regarded expert and thought leader. She has been a guest speaker for numerous local and national organizations. Notably, Nicole was also selected for inclusion into the National Black Lawyers Top 100 , an elite network of successful and influential lawyers with reputations for providing excellent legal representation in their respective practice areas.

Nicole has more than 20 years of relevant experience across labor and employment law and compliance. She earned her J.D. from Howard University School of Law and her B.A. from Spelman College.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

ELC-C
ELC-L

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye